0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover3457.13%IV-32.07%PremiumMay 17, 2024Expiry Date2.36Intrinsic Value100Multiplier-5DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type0.9638Delta0.0362Gamma--Leverage Ratio-3.5447Theta0.0000Rho0.00Eff Leverage0.0001Vega
Shattuck Labs Stock Discussion
NEWS
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Shattuck Labs, Inc. reveals preclinical data at AACR Annual Meeting 2024 showing TRIM7 inhibition can combat immune checkpoint therapy resistance. TRIM7 inhibitors may reverse acquired resistance to PD-1/L1 blockade, potentially benefiting cancer patients.
No comment yet